ArticleSubstance abuse treatment, prevention, and policy2026
Managing benzodiazepine dependence arising from use of the adulterated opioid supply: a commentary.
Article in Substance abuse treatment, prevention, and policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing presence of benzodiazepine-adulterated opioids in the unregulated drug supply poses significant challenges for clinicians treating people with opioid use disorder. This commentary highlights key areas of uncertainty and emerging agreement on screening, risk assessment, withdrawal timelines, and treatment approaches for individuals using benzodiazepine-adulterated opioids. It also identifies gaps in community-based support, the effectiveness of drug checking, and the role of medications for opioid use disorder in managing opioid-benzodiazepine withdrawal. Together, these scenarios demonstrate rapidly evolving challenges and the need to refine clinical practices in order to improve care for individuals affected by the evolving unregulated drug supply.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.